The global diabetes care market reached $125.7 billion, with therapeutics alone accounting for $52.5 billion and insulin adding $39.9 billion. At the care level, 4.5 million people in England were living with a diabetes diagnosis and cardiovascular disease accounted for 19% of diabetes related deaths worldwide. This dataset pulls together the market, treatment, and outcome figures shaping diabetes care.
Key Takeaways
- In 2022, the global diabetes care devices market was estimated at $20.8 billion (forecast base year; vendor research summary)
- In 2023, the global diabetes care market was valued at $125.7 billion (forecast base year; vendor research summary)
- In 2023, the global insulin market was valued at $39.9 billion (forecast base year; vendor research summary)
- In England, 4.5 million people were diagnosed with diabetes in 2023 (NHS Diabetes estimate)
- Over 1 billion blood glucose test strips were used per year in the U.S. in 2021 (industry/market report estimate cited in U.S. documents)
- In England, diabetes was responsible for 1.9 million hospital admissions over 2017–2020 combined (NHS England analysis)
- In 2019, metformin was the most commonly prescribed drug for diabetes in England with 8.5 million prescriptions (NHSBSA prescribing data)
- HbA1c lowering of about 1% reduces risk of diabetes complications by 14% overall (UKPDS meta-analysis figure)
- Each 1% reduction in HbA1c is associated with a 21% reduction in diabetes-related death (meta-analysis reported in Lancet/UKPDS follow-up summaries)
- Intensive glucose control reduced the risk of microvascular complications by about 25% in the UKPDS (trial results)
From £4.5 million diagnosed in England to huge global markets and trial proven HbA1c benefits, diabetes care keeps expanding.
Related reading
01 · Category
Market Size6 stats
01
In 2022, the global diabetes care devices market was estimated at $20.8 billion (forecast base year; vendor research summary)
02
In 2023, the global diabetes care market was valued at $125.7 billion (forecast base year; vendor research summary)
03
In 2023, the global insulin market was valued at $39.9 billion (forecast base year; vendor research summary)
04
In 2023, the global diabetes diagnostics market was valued at $11.2 billion (forecast base year; vendor research summary)
05
In 2023, the global diabetes monitoring market was valued at $13.3 billion (forecast base year; vendor research summary)
06
In 2023, the global diabetes therapeutics market was valued at $52.5 billion (forecast base year; vendor research summary)
Interpretation
Market Size Interpretation
For the market size view, diabetes-related spending is clearly broadening across the care ecosystem in 2023, when the overall diabetes care market reached $125.7 billion alongside a large therapeutics segment of $52.5 billion and major diagnostics and monitoring markets of $11.2 billion and $13.3 billion.
02 · Category
Diagnosis & Care1 stats
01
In England, 4.5 million people were diagnosed with diabetes in 2023 (NHS Diabetes estimate)
Interpretation
Diagnosis & Care Interpretation
In England, 4.5 million people were diagnosed with diabetes in 2023, underscoring the large and ongoing need for timely diagnosis and effective ongoing care within the Diagnosis and Care category.
More related reading
03 · Category
Industry Trends6 stats
01
Over 1 billion blood glucose test strips were used per year in the U.S. in 2021 (industry/market report estimate cited in U.S. documents)
02
In England, diabetes was responsible for 1.9 million hospital admissions over 2017–2020 combined (NHS England analysis)
03
In 2019, metformin was the most commonly prescribed drug for diabetes in England with 8.5 million prescriptions (NHSBSA prescribing data)
04
In 2020, there were 1.2 million diabetes-related hospital stays in England (NHS Digital hospital episode statistics)
05
In 2021, cardiovascular disease accounted for 19% of diabetes-related deaths globally (GBD study; reported in Lancet/WHO summaries)
06
In 2017, the global rate of diabetes-related mortality increased by 0.9% per year in 1990–2017 (Global Burden of Disease study summary on mortality trends)
Interpretation
Industry Trends Interpretation
Across major markets, diabetes is driving sustained demand and cost, shown by the US using over 1 billion blood glucose test strips yearly in 2021 and England seeing 1.2 million diabetes-related hospital stays in 2020 alongside rising global mortality patterns like a 0.9% annual increase in diabetes-related deaths from 1990 to 2017.
04 · Category
Clinical Outcomes15 stats
01
HbA1c lowering of about 1% reduces risk of diabetes complications by 14% overall (UKPDS meta-analysis figure)
02
Each 1% reduction in HbA1c is associated with a 21% reduction in diabetes-related death (meta-analysis reported in Lancet/UKPDS follow-up summaries)
03
Intensive glucose control reduced the risk of microvascular complications by about 25% in the UKPDS (trial results)
04
In UKPDS, intensive therapy reduced the risk of any diabetes-related endpoint by 12% over 10 years (trial follow-up; UKPDS)
05
In ACCORD, intensive glucose control increased all-cause mortality by 22% and was stopped early (ACCORD trial)
06
In ADVANCE, intensive glucose control reduced the risk of major macrovascular events by 10% (ADVANCE trial)
07
In EMPA-REG OUTCOME, empagliflozin reduced all-cause mortality by 32%
08
In LEADER, liraglutide reduced the risk of cardiovascular death by 22% (median follow-up 3.8 years)
09
In SUSTAIN-6, semaglutide reduced the risk of major adverse cardiovascular events by 26%
10
In DAPA-HF (in heart failure patients with or without diabetes), dapagliflozin reduced the composite endpoint by 26% (hazard ratio 0.74)
11
In UKPDS, metformin therapy reduced diabetes-related death by 42% compared with conventional therapy in overweight participants (UKPDS 34)
12
In DCCT, intensive therapy reduced the risk of neuropathy by 60% (DCCT)
13
In the UKPDS follow-up (10 years), each 1 mmol/mol decrease in HbA1c was associated with a 14% reduction in microvascular endpoints (UKPDS outcomes relationship)
14
Metformin reduced the incidence of diabetes by 31% in the DPP at 3 years (diabetes prevention trial)
15
In the Finnish Diabetes Prevention Study, lifestyle intervention reduced the incidence of type 2 diabetes by 58% over 4 years (peer-reviewed results)
Interpretation
Clinical Outcomes Interpretation
For clinical outcomes in diabetes, lowering HbA1c and intensifying glucose control generally improves key complication endpoints, with about a 1% HbA1c drop linked to roughly a 14% overall reduction in complications and a 21% cut in diabetes-related death, even though trials like ACCORD show that intensive therapy can carry risks such as a 22% rise in all-cause mortality.
report visual · Breakdown
Diabetes care market size by segment (2023)
In 2023, the global diabetes care value is spread across therapeutics, care, and diagnostics/monitoring categories.
42%
In UKPDS, metformin therapy reduced diabetes-related death by 42% compared with conventional therapy in overweight parti
58%
In the Finnish Diabetes Prevention Study, lifestyle intervention reduced the incidence of type 2 diabetes by 58% over 4
source-verifieddiabetesjournals.org · nejm.org
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Diabetes Global Statistics. Gitnux. https://gitnux.org/diabetes-global-statistics
MLA
Megan Gallagher. "Diabetes Global Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diabetes-global-statistics.
Chicago
Megan Gallagher. 2026. "Diabetes Global Statistics." Gitnux. https://gitnux.org/diabetes-global-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)